Calidi Biotherapeutics, Inc.
CLDICalidi Biotherapeutics, Inc. (CLDI) is a biotechnology company focused on developing advanced cell-based immunotherapies for cancer and infectious diseases. The company leverages proprietary platform technologies, including its tumor-targeting and immune-activating cell systems, to create innovative treatments aimed at improving patient outcomes.
Company News
Calidi Biotherapeutics is hosting an investor webinar to discuss its RedTail platform, an engineered viral therapy designed to deliver genetic medicines to tumor sites. The company aims to advance its technology towards IND filing by end of 2026, targeting oncology markets projected to exceed $560 billion by 2033.
Calidi Biotherapeutics completed a public offering, raising $6.9 million by selling common stock units and pre-funded warrant units, with Ladenburg Thalmann & Co. Inc. acting as sole book-running manager.
Calidi Biotherapeutics will implement a 1-for-12 reverse stock split of its outstanding common stock, effective August 5, 2025, to optimize market dynamics and investor appeal.
Calidi Biotherapeutics is developing a groundbreaking genetic medicine platform using engineered viruses to precisely target and treat metastatic cancers, with promising preclinical data presented at AACR and ASCO conferences.
Calidi Biotherapeutics, a clinical-stage biotechnology company, announced the closing of a $4.25 million public offering of 5,000,000 shares of common stock at $0.85 per share. The company is developing targeted antitumor virotherapies.
